tiprankstipranks
Trending News
More News >
Eckert & Ziegler Strahlen- und Medizintechnik AG (DE:EUZ)
XETRA:EUZ

Eckert & Ziegler Strahlen und Medizintechnik (EUZ) AI Stock Analysis

Compare
15 Followers

Top Page

DE

Eckert & Ziegler Strahlen und Medizintechnik

(XETRA:EUZ)

Rating:78Outperform
Price Target:
€75.00
▲(14.77%Upside)
The overall score is driven by a strong financial performance and positive technical indicators. The company's financial health is solid, with impressive revenue growth and cash flow generation, which supports future growth. Technical analysis shows strong bullish momentum, although the stock is approaching overbought levels. The valuation appears stretched, with a high P/E ratio, but this is partially offset by the dividend yield.

Eckert & Ziegler Strahlen und Medizintechnik (EUZ) vs. iShares MSCI Germany ETF (EWG)

Eckert & Ziegler Strahlen und Medizintechnik Business Overview & Revenue Model

Company DescriptionEckert & Ziegler Strahlen und Medizintechnik (EUZ) is a leading German company specializing in the development, production, and sale of isotope technology components for medical, scientific, and industrial applications. The company's core products and services include radiopharmaceuticals, radiation therapy devices, and industrial radiometry equipment. Operating globally, Eckert & Ziegler serves clients in healthcare, research, and industrial sectors, providing innovative solutions for cancer treatment, diagnostic imaging, and radiation measurement.
How the Company Makes MoneyEckert & Ziegler generates revenue through the sale of its radiopharmaceuticals for nuclear medicine, which are used in diagnostic imaging and cancer therapy. The company also earns income from its radiation therapy devices, which are utilized in hospitals and clinics for treating various cancers. Additionally, Eckert & Ziegler's industrial segment provides radiation measurement and imaging solutions for a variety of industries. Significant partnerships with healthcare institutions and research organizations enhance its market reach, further contributing to its earnings.

Eckert & Ziegler Strahlen und Medizintechnik Financial Statement Overview

Summary
Eckert & Ziegler Strahlen und Medizintechnik exhibits solid financial health with strong revenue growth, robust profitability margins, and a stable balance sheet. Cash flow generation is impressive, supporting future investment and growth opportunities. Continued focus on cost management and leveraging efficiencies will further enhance financial performance.
Income Statement
82
Very Positive
The company demonstrates strong revenue growth with a 20.22% increase from 2023 to 2024. Gross profit margin improved slightly, indicating good cost management. However, the net profit margin, while positive, suggests room for improvement in controlling expenses. EBIT and EBITDA margins remained robust, enhancing overall profitability.
Balance Sheet
75
Positive
The balance sheet is stable, with a solid equity ratio of 50.51% and a manageable debt-to-equity ratio of 0.25, indicating prudent financial leverage. Return on equity is healthy, reflecting efficient use of equity capital. The consistent growth in stockholders' equity further supports financial stability.
Cash Flow
78
Positive
Cash flow analysis shows a significant increase in free cash flow, with a 133.83% growth from 2023 to 2024, highlighting improved cash generation capabilities. The operating cash flow to net income ratio is strong, indicating effective conversion of income to cash. Free cash flow to net income ratio also underscores efficient cash management.
Breakdown
Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
295.85M246.09M222.26M180.44M176.14M
Gross Profit
143.16M116.34M106.78M91.08M86.53M
EBIT
61.07M47.00M46.97M46.03M35.24M
EBITDA
80.96M59.67M57.90M56.68M43.05M
Net Income Common Stockholders
33.28M26.30M29.28M34.53M21.29M
Balance SheetCash, Cash Equivalents and Short-Term Investments
118.36M68.00M82.70M95.02M88.61M
Total Assets
442.40M439.36M416.84M347.73M292.00M
Total Debt
55.34M56.30M49.59M26.97M20.40M
Net Debt
-62.88M-11.69M-33.11M-66.69M-67.07M
Total Liabilities
217.18M215.27M203.21M155.20M143.08M
Stockholders Equity
223.45M222.18M212.07M187.39M147.82M
Cash FlowFree Cash Flow
49.38M21.12M3.17M5.00M27.88M
Operating Cash Flow
66.57M46.95M34.30M33.85M36.79M
Investing Cash Flow
-16.59M-42.74M-41.04M-23.59M-13.35M
Financing Cash Flow
-9.99M-9.28M-5.71M-6.06M-12.96M

Eckert & Ziegler Strahlen und Medizintechnik Technical Analysis

Technical Analysis Sentiment
Positive
Last Price65.35
Price Trends
50DMA
59.04
Positive
100DMA
57.89
Positive
200DMA
50.01
Positive
Market Momentum
MACD
1.86
Negative
RSI
57.24
Neutral
STOCH
78.49
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:EUZ, the sentiment is Positive. The current price of 65.35 is above the 20-day moving average (MA) of 64.15, above the 50-day MA of 59.04, and above the 200-day MA of 50.01, indicating a bullish trend. The MACD of 1.86 indicates Negative momentum. The RSI at 57.24 is Neutral, neither overbought nor oversold. The STOCH value of 78.49 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:EUZ.

Eckert & Ziegler Strahlen und Medizintechnik Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
DEEUZ
78
Outperform
€1.36B39.5117.48%3.12%15.89%14.62%
DECOP
64
Neutral
€1.16B33.045.26%4.53%-2.84%-24.28%
DEFYB
63
Neutral
€479.59M5.89-26.06%-10.32%-250.76%
58
Neutral
€1.39B44.96-4.72%0.27%-18.82%-113.85%
54
Neutral
$5.37B3.26-45.10%3.30%16.81%0.02%
DEBIO
50
Neutral
€1.39B64.15-4.72%0.10%-18.82%-113.85%
DEEVT
49
Neutral
€1.31B-20.51%1.50%-127.76%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
DE:EUZ
Eckert & Ziegler Strahlen und Medizintechnik
65.35
25.49
63.93%
DE:COP
CompuGroup Medical
22.04
-2.68
-10.84%
DE:EVT
Evotec
7.40
-0.20
-2.66%
DE:BIO
Biotest
40.40
-0.60
-1.46%
DE:BIO3
Biotest
29.60
2.80
10.45%
DE:FYB
Formycon AG
27.15
-19.25
-41.49%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.